Percardia

Percardia was a medical device company specializing in the development of percutaneous myocardial revascularization (PMR) technologies. The company's lead system was designed to treat patients suffering from severe, chronic angina who were not suitable candidates for conventional treatments like coronary artery bypass grafting or balloon angioplasty. By using a catheter-based approach to create small channels in the heart muscle, the technology aimed to stimulate angiogenesis and improve myocardial perfusion. Percardia's innovative approach provided a minimally invasive alternative to surgical transmyocardial revascularization (TMR). The company was acquired by Medtronic in 2000 for approximately $100 million, allowing the integration of PMR technology into Medtronic's extensive cardiovascular portfolio.